Biznes · 17/11/20261 daq o‘qish
Onward Therapeutics NT$900 million (taxminan 28 million AQSH) B-sinf finansirovaniyani yakunladi va klinika darajasidagi onkologiya pipeline-ni rivojlantirish uchun xodisalarni davom ettiradi
Mahalliy avtomatik tarjima · Manbaning asl tili
Xulosa
Onward Therapeutics global ma'muriyatini Tayvan ga ko'chirganidan keyin birinchi marta kapitalni oshirgan; Kompaniya 2027-yil oxirigacha Yangi Sharq bozori hisobga olinuvchi hissadorlar paneliga (Emerging Stock Board) ro'yxatdan o'tishni maqsad qilmoqda. TAIPEI, EPALINGES va PARIS, 2026-yil 17-november — Onward Therapeutics, Inc. ("Onward Therapeutics" yoki "Kompaniya") bugun...